Genfit (GNFT) Competitors $3.50 +0.07 (+1.89%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNFT vs. DNTH, QURE, CRMD, ETNB, CGEM, PHAR, LENZ, ABUS, IMNM, and EOLSShould you be buying Genfit stock or one of its competitors? The main competitors of Genfit include Dianthus Therapeutics (DNTH), uniQure (QURE), CorMedix (CRMD), 89bio (ETNB), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), LENZ Therapeutics (LENZ), Arbutus Biopharma (ABUS), Immunome (IMNM), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Genfit vs. Dianthus Therapeutics uniQure CorMedix 89bio Cullinan Therapeutics Pharming Group LENZ Therapeutics Arbutus Biopharma Immunome Evolus Dianthus Therapeutics (NASDAQ:DNTH) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is DNTH or GNFT more profitable? Genfit has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Genfit's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,250.32% -21.68% -20.88% Genfit N/A N/A N/A Does the MarketBeat Community prefer DNTH or GNFT? Genfit received 45 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 69.39% of users gave Genfit an outperform vote. CompanyUnderperformOutperformDianthus TherapeuticsOutperform Votes2395.83% Underperform Votes14.17%GenfitOutperform Votes6869.39% Underperform Votes3030.61% Do institutionals & insiders have more ownership in DNTH or GNFT? 47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 16.6% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 4.2% of Genfit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, DNTH or GNFT? Genfit has higher revenue and earnings than Dianthus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$2.83M209.19-$43.56M-$2.50-8.00Genfit$41.31M4.24-$31.27MN/AN/A Does the media refer more to DNTH or GNFT? In the previous week, Dianthus Therapeutics had 1 more articles in the media than Genfit. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 2 mentions for Genfit. Dianthus Therapeutics' average media sentiment score of 0.82 beat Genfit's score of 0.24 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genfit 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate DNTH or GNFT? Dianthus Therapeutics currently has a consensus price target of $46.43, indicating a potential upside of 132.14%. Genfit has a consensus price target of $13.00, indicating a potential upside of 270.90%. Given Genfit's higher probable upside, analysts plainly believe Genfit is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, DNTH or GNFT? Dianthus Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. SummaryDianthus Therapeutics beats Genfit on 10 of the 17 factors compared between the two stocks. Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGenfitBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$175.25M$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E RatioN/A45.5689.3417.36Price / Sales4.24275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book2.373.965.314.79Net Income-$31.27M-$41.02M$122.54M$225.00M7 Day Performance1.89%0.19%0.59%2.62%1 Month Performance-7.76%-1.72%2.55%3.81%1 Year Performance4.94%-2.23%25.29%20.10% Genfit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGenfit1.646 of 5 stars$3.51+1.9%$13.00+270.9%+4.9%$175.25M$41.31M0.00120Short Interest ↑News CoveragePositive NewsDNTHDianthus Therapeutics1.8833 of 5 stars$22.63-6.5%$46.43+105.2%+67.4%$669.78M$5.37M-9.0580Short Interest ↑QUREuniQure3.7803 of 5 stars$13.72-0.9%$33.88+146.9%+153.2%$668.75M$28.59M-2.77500CRMDCorMedix2.6144 of 5 stars$11.01-1.6%$15.67+42.3%+273.3%$668.05M$12.26M-13.5930ETNB89bio2.1444 of 5 stars$6.23-4.3%$30.33+386.9%-42.8%$661.17MN/A-2.1440Analyst ForecastShort Interest ↑News CoverageCGEMCullinan Therapeutics2.0234 of 5 stars$10.98-1.9%$31.67+188.4%-10.9%$639.34M$18.94M-3.8730PHARPharming Group2.5695 of 5 stars$9.37-3.5%$27.00+188.2%-17.5%$635.61M$285.75M-36.04280Positive NewsGap DownLENZLENZ Therapeutics2.1437 of 5 stars$22.61-2.6%$35.40+56.6%N/A$621.80MN/A0.00110Short Interest ↑Positive NewsABUSArbutus Biopharma2.7541 of 5 stars$3.27-0.6%$5.50+68.2%+35.6%$619.64M$6.74M-7.6073IMNMImmunome1.8335 of 5 stars$9.83-7.3%$28.83+193.3%-26.0%$613.56M$10.13M-1.2140Short Interest ↑EOLSEvolus4.0046 of 5 stars$9.64-3.6%$23.00+138.6%-11.3%$610.41M$248.33M-10.59170 Related Companies and Tools Related Companies Dianthus Therapeutics Alternatives uniQure Alternatives CorMedix Alternatives 89bio Alternatives Cullinan Therapeutics Alternatives Pharming Group Alternatives LENZ Therapeutics Alternatives Arbutus Biopharma Alternatives Immunome Alternatives Evolus Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNFT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
